Irritable Bowel Syndrome Clinical Trial
Official title:
Phase I, Open Label Safety Study of VSL#3 in Adults With Irritable Bowel Syndrome
Determine the safety and preliminary effectiveness of VSL#3 in adults with IBS.
Recent studies performed outside the U.S. and/or prior to recent FDA requirements suggest
that the probiotics in VSL#3 may be effective in IBS in adults. Because there is a
significant unmet need for improved IBS therapies to prevent frequent exacerbations that
lead to unscheduled health care, we will conduct a safety study of the probiotic VSL#3.
Preliminary studies suggest that probiotics such as VSL#3 are effective in the treatment of
adults with IBS but safety studies have not been carried out. A safety study of VSL#3 has
been carried out in adult asthmatics that demonstrated no significant adverse effects.
Before a trial of VSL#3 can be performed in children with IBS, the FDA has requested that a
safety trial be conducted in adults with IBS.
Consent will be obtained from the subject.
Adults who meet the criteria for irritable bowel syndrome will be recruited and studied.
They will have been diagnosed by an adult gastroenterologist.
During a baseline one week period, the subjects will keep a diary of pain episodes, pain
severity, pain-induced interference with activity, and stooling pattern (i.e.,
pain/activity/stool diary).
Following the baseline period, the subjects will be randomized into either a 4 week or 8
week treatment period with the probiotic. The treatment will be open label. During the
treatment period, subjects will keep the diary for pain and stooling habits and a daily
record of symptoms (i.e., daily temperature monitoring).
At the end of the treatment period the pain/stool/activity diary will be repeated. Four
weeks after the treatment period ends a follow-up phone call will be made to participants to
check on their pain and stooling patterns.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |